$ cat jobs/manager-market-access-pricing-eversana-3643659c3810.json
Manager, Market Access & Pricing
THE POSITION : The purpose of this role is to ensure that project teams attain optimal reimbursement for our client’s products; the core responsibilities will include leading project teams that develop and leverage evidence (clinical, economic, and humanistic) to demonstrate the value of treatments to Canadian payers. This position is responsible for leading the execution of our clients’ national, provincial, and private strategic market access plans to achieve timely reimbursement. ESSENTIAL DUTIES AND RESPONSIBILITIES: Our employees are tasked with delivering excellent business results through the efforts of their teams. These results are achieved by: Leading project teams on submissions to the Canada’s Drug Agency L’Agence des medicaments du Canada (CDA-AMC), Institut National d'Excellence en Santé et Services Sociaux (INESSS),, provincial agencies/programs, and private payers. Managing the submission process start to finish including creating detailed workplans, liaising with the client including cross-functional support, handling all touchpoints with health technology assessment (HTA) organizations, and managing pull-through processes. Coordinating across internal workstreams to ensure strategic consistency and that project timelines are met. Conducting background research to support submission strategy and submission dossier components. Developing clinical summaries/clinical evidence templates, budget impact analyses, and all other required submission components for HTA filings to CDA-AMC and INESSS, provincial payers (drug plans and cancer agencies) and private drug plans. Preparing slide decks and attending meetings with CDA-AMC /INESSS, public drug programs, private payers, the pCPA and advisory boards. Interviewing key opinion leader clinicians regarding the standards of care in treating their patients to attain strategic insights to optimize product reimbursement. Preparing for and supporting the facilitation of advisory boards with ex-payers, and in some